Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alida Benfante

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Frontiers in Immunology|July 17, 2023
Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational studySanti Nolasco, Andrea Portacci, Raffaele Campisi, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 22, 2021
Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter StudySanti Nolasco, Claudia Crimi, Corrado Pelaia, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|October 5, 2021
Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub-phenotypes of response identified by cluster analysisDanilo Di Bona, Claudia Crimi, Angela Maria D'Uggento, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|October 11, 2024
Cluster Analysis Identifies Patients With Severe Eosinophilic Asthma Who Achieve Super-Response and Remission With MepolizumabDanilo Di Bona, Massimo Bilancia, Claudia Crimi, et al.
Frontiers in Immunology|April 17, 2023
Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polypsCorrado Pelaia, Alida Benfante, Maria Teresa Busceti, et al.
Respiration; International Review of Thoracic Diseases|April 10, 2026
Sex comparison in clinical presentation, response, and remission in severe type-2 asthma patients treated with biologics: a real-world analysis from the "Southern Italy Network on Severe Asthma Therapy"Giulia Scioscia, Carla Maria Irene Quarato, Alida Benfante, et al.
Journal of Clinical Medicine|July 31, 2020
The Hidden Burden of Severe Asthma: From Patient Perspective to New Opportunities for CliniciansNicola Scichilone, Peter John Barnes, Salvatore Battaglia, et al.
Respirology (Carlton, Vic.)|June 7, 2024
Sustained remission induced by 2 years of treatment with benralizumab in patients with severe eosinophilic asthma and nasal polyposisCorrado Pelaia, Claudia Crimi, Alida Benfante, et al.
Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace|March 21, 2018
Inhalation therapy in the next decade: Determinants of adherence to treatment in asthma and COPDClaudio F Donner, Sandro Amaducci, Elena Bacci, et al.
Pulmonary Pharmacology & Therapeutics|March 26, 2017
Asthma management in a specialist setting: Results of an Italian Respiratory Society surveyFulvio Braido, Ilaria Baiardini, Pietro Alleri, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Frontiers in Immunology|July 17, 2023
Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational studySanti Nolasco, Andrea Portacci, Raffaele Campisi, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 22, 2021
Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter StudySanti Nolasco, Claudia Crimi, Corrado Pelaia, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|October 5, 2021
Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub-phenotypes of response identified by cluster analysisDanilo Di Bona, Claudia Crimi, Angela Maria D'Uggento, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|October 11, 2024
Cluster Analysis Identifies Patients With Severe Eosinophilic Asthma Who Achieve Super-Response and Remission With MepolizumabDanilo Di Bona, Massimo Bilancia, Claudia Crimi, et al.
Frontiers in Immunology|April 17, 2023
Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polypsCorrado Pelaia, Alida Benfante, Maria Teresa Busceti, et al.
Respiration; International Review of Thoracic Diseases|April 10, 2026
Sex comparison in clinical presentation, response, and remission in severe type-2 asthma patients treated with biologics: a real-world analysis from the "Southern Italy Network on Severe Asthma Therapy"Giulia Scioscia, Carla Maria Irene Quarato, Alida Benfante, et al.
Journal of Clinical Medicine|July 31, 2020
The Hidden Burden of Severe Asthma: From Patient Perspective to New Opportunities for CliniciansNicola Scichilone, Peter John Barnes, Salvatore Battaglia, et al.
Respirology (Carlton, Vic.)|June 7, 2024
Sustained remission induced by 2 years of treatment with benralizumab in patients with severe eosinophilic asthma and nasal polyposisCorrado Pelaia, Claudia Crimi, Alida Benfante, et al.
Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace|March 21, 2018
Inhalation therapy in the next decade: Determinants of adherence to treatment in asthma and COPDClaudio F Donner, Sandro Amaducci, Elena Bacci, et al.
Pulmonary Pharmacology & Therapeutics|March 26, 2017
Asthma management in a specialist setting: Results of an Italian Respiratory Society surveyFulvio Braido, Ilaria Baiardini, Pietro Alleri, et al.
Pageof 8